Decellularizing Human Hearts: Characterizing Native Cardiac Matrix for Clinical Translation

Guyette, Jacques P.; Song, Justin C. W.; Chuang, Warren; Ng, Richard P.; Charest, Jonathan M.; Gaudette, Glenn R.; Vacanti, Joseph P.; Ott, Harald C.

doi:10.1016/j.healun.2013.01.918

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,[26][27][28] For example, Sanchez et al reported the decellularization of 23 whole human hearts with SDS for 4-5 days. 27 Guyette et al also reported the decellularization of porcine and human hearts.…”

Section: Decellularizationmentioning

confidence: 99%

“…27 Guyette et al also reported the decellularization of porcine and human hearts. 26,28 The methods used for decellularizing human hearts were developed based on published protocols by the same authors for decellularizing hearts from rats 12 and pigs. 20 Retrograde perfusion of 1% (w/v) SDS through the aorta was performed after perfusing the organs with heparin solution at constant pressure of 60 mm Hg.…”

Section: Decellularizationmentioning

confidence: 99%

See 1 more Smart Citation

Strategies and Processes to Decellularize and Recellularize Hearts to Generate Functional Organs and Reduce the Risk of Thrombosis

Momtahan

Sukavaneshvar²,

Roeder

et al. 2015

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

Heart failure is one of the leading causes of death in the United States. Current therapies, such as heart transplants and bioartificial hearts, are helpful, but not optimal. Decellularization of porcine whole hearts followed by recellularization with patient-specific human cells may provide the ultimate solution for patients with heart failure. Great progress has been made in the development of efficient processes for decellularization, and the design of automated bioreactors. Challenges remain in selecting and culturing cells, growing the cells on the decellularized scaffolds without contamination, characterizing the regenerated organs, and preventing thrombosis. Various strategies have been proposed to prevent thrombosis of blood-contacting devices, including reendothelization and the creation of nonfouling surfaces using surface modification technologies. This review discusses the progress and remaining challenges involved with recellularizing whole hearts, focusing on the prevention of thrombosis.

show abstract

Section: Decellularizationmentioning

confidence: 99%

Section: Decellularizationmentioning

confidence: 99%

Strategies and Processes to Decellularize and Recellularize Hearts to Generate Functional Organs and Reduce the Risk of Thrombosis

Momtahan

Sukavaneshvar²,

Roeder

et al. 2015

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

show abstract

Cardiovascular Tissue Engineering: Preclinical Validation to Bedside Application

et al. 2016

View full text Add to dashboard Cite

Advancements in biomaterial science and available cell sources have spurred the translation of tissue-engineering technology to the bedside, addressing the pressing clinical demands for replacement cardiovascular tissues. Here, the in vivo status of tissue-engineered blood vessels, heart valves, and myocardium is briefly reviewed, illustrating progress toward a tissue-engineered heart for clinical use.

show abstract

Decellularizing Human Hearts: Characterizing Native Cardiac Matrix for Clinical Translation

Cited by 2 publications

References 0 publications

Strategies and Processes to Decellularize and Recellularize Hearts to Generate Functional Organs and Reduce the Risk of Thrombosis

Strategies and Processes to Decellularize and Recellularize Hearts to Generate Functional Organs and Reduce the Risk of Thrombosis

Cardiovascular Tissue Engineering: Preclinical Validation to Bedside Application

Contact Info

Product

Resources

About